143748-18-9

中文名称 PACAP (6-38), HUMAN, OVINE, RAT

英文名称 PACAP 6-38

CAS 143748-18-9

分子式 C182H300N56O45S

分子量 4024.74

MOL 文件 143748-18-9.mol

更新日期 2024/07/07 16:58:00

143748-18-9 结构式

基本信息物理化学性质常见问题列表

基本信息

中文别名

HUMAN PACAP(6-38)

英文别名

PACAP 6-38
PACAP-38 (6-38)
HumanPACAP(6-38)
PACAP (6-38), HUMAN, OVINE, RAT
PACAP (6-38) (HUMAN, SHEEP, RAT)
PACAP (HUMAN, 6-38) (OVINE, RAT)
FTDSYSRYRKQMAVKKYLAAVLGKRYKQRVKNK-NH2
PACAP (6-38), AMIDE, HUMAN, OVINE, RAT
PACAP-38 (6-38) (HUMAN, CHICKEN, MOUSE, OVINE, PORCINE, RAT)
PITUITARY ADENYLATE ACTIVATING POLYPEPTIDE (6-38) (HUMAN, OVINE, RAT)

物理化学性质

储存条件-15°C

溶解度H2OPeptide Solubility and Storage Guidelines:1.??Calculate the length of the peptide.2.??Calculate the overall charge of the entire peptide according to the following table:3.??Recommended solution:

形态固体

水溶解性Soluble to 2 mg/ml in water

常见问题列表

生物活性

PACAP (6-38), human, ovine, rat 是一种有效的 PACAP 受体拮抗剂。PACAP (6-38) 作用于 PACAP I 型受体，PACAP II 型受体 VIP1 和 PACAP II 型受体 VIP2，IC50 分别为 30 nM，600 nM 和 40 nM。

靶点

IC50: 30 nM (PACAP type I receptor), 600 nM (PACAP type II receptor VIP ₁ ), 40 nM (PACAP type II receptor VIP ₂ )

体外研究

An increase of dopamine (DA) content by HPLC analysis and/or cell proliferation identified by MTT assay by Dexamethasone (DEX) is also observed which can be inhibited by PACAP (6-38) at concentration sufficient to block PACAP type 1 (PAC1) receptor. Pretreatment with PAC1 receptor antagonist PACAP (6-38) at 0.1 or 1 μM for 2 h significantly blocks this increase of DA content by 1 μM DEX. The MTT assay shows that DEX increases cell proliferation. Moreover, this action is also inhibited by the pre-incubation of PACAP (6-38). PACAP (6-38) at 1μM shows no effect on DA content and cell proliferation for 24 h. However, PACAP (6-38) at 0.3 μM has been mentioned to reduce the spontaneous tyrosine hydroxylase (TH) accumulation in differentiated retinal cultured cells for 5 days.

体内研究

Intravesical administration of the PAC1 receptor antagonist, PACAP (6-38) (300 nM), significantly (p≤0.01) increases intercontraction interval (2.0-fold) and void volume (2.5-fold) in NGF-OE mice. Intravesical instillation of PACAP (6-38) also decreases baseline bladder pressure in NGF-OE mice. Intravesical administration of PACAP (6-38) (300 nM) significantly (p≤0.01) reduces pelvic sensitivity in NGF-OE mice but is without effect in WT mice.